A Silver Lining for British Biotech and ImmunoGen
Executive Summary
British Biotech acquired EU and Japanese rights to ImmunoGen's preclinical cancer compound, huN901-DM1. As part of the deal, British Biotech also will be responsible, on a contract basis, for US clinical development of the drug. ImmunoGen retains US product rights, allowing it to establish the drug's value before out-licensing. For British Biotech, which has reorganized, the deal is typical of its new strategy of emphasizing its development capabilities, acting in a CRO-like manner for other companies. ImmunoGen is also enjoying something of a renaissance, having inked two deals with Genentech, which will apply ImmunoGen technology to develop monoclonal antibody/drug conjugates.
You may also be interested in...
UK Biotech Learns the Hard Way
A bunch of UK biotech firms are in trouble, some forced to restructure and others to seek financing on miserably expensive terms. All wish they'd raised more money during the funding bonanza of 2000. Challenging times such as these reveal lingering cracks--and lack of experience--in strategy and business management. This suggests that UK industry, although it has matured significantly since the brutal blow to confidence dealt by a major product failure at British Biotech during the sector's tender early years, still has some way to go.
Pharma Can Pursue Claims Against Providers For 340B Duplicate Discounts In Medicaid Managed Care, HRSA Says
The statement, which is part of a final rule on the 340B administrative dispute resolution process, could facilitate manufacturer efforts to seek repayments from hospitals in such cases.
The Aspirin Test For AI?
US FDA Commissioner Robert Califf tells Congress that regulators don’t have to know how artificial intelligence works in medicine, but must make very sure it actually does work.